📇 Rhumatologue · PARIS CEDEX 10 · (75) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
30 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Dissecting the role of mutations in Adenosine Deaminase Acting on RNA 1 (ADAR1) and other interferon related genes in the pathogenesis of psoriasis
Doctorant·e : Florence Assan
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
SpeckSeq enables high-throughput functional stratification of MEFV variants in autoinflammatory diseases
2026ArticleJournal of Experimental Medicine
Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment
2024ArticleNature Communications
Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort
2023ArticleClinical and Experimental Dermatology
Human papilloma virus‐16‐specific CD8+ T‐cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus
2023ArticleExperimental Dermatology
IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis
2023ArticleJournal of Investigative Dermatology
Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry
2023ArticleBritish Journal of Dermatology
Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey
2022ArticleBritish Journal of Dermatology
A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study
2022ArticleDermatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP NUP SITE SAINT LOUIS
1 AV CLAUDE VELLEFAUX, 75475 PARIS CEDEX 10
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2021
Expert review of clinical immunology · 2022
BMJ open · 2021
Introduction Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan, Taiwan and Thailand, associated evidence is largely based on uncontrolled studies in which acute flares were not directly assessed. Therefore, there is a high unmet need to investigate new rapid-acting effective treatments that resolve symptoms associated with acute GPP flares. A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare. Here, we present the design and rationale of Effisayil 1, a global, Phase II, placebo-controlled study to evaluate the efficacy, safety and tolerability of spesolimab in patients presenting with an acute GPP flare. Methods and analysis At least 51 patients with an acute GPP flare will be randomised 2:1 to receive a single 900 mg intravenous dose of spesolimab or placebo and followed for up to 28 weeks. The primary endpoint is a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (pustule clearance) at Week 1. The key secondary endpoint is a GPPGA score of 0 or 1 (clear or almost clear) at Week 1. Safety will be assessed over the study duration by the occurrence of treatment-emergent adverse events. Blood and skin biopsies will be collected to assess biomarkers. Superiority of spesolimab over placebo in the proportion of patients achieving the primary and key secondary endpoints will be evaluated. Ethics and dissemination The study complies with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation’s Good Clinical Practice and local regulations. Ethics committee approvals have been obtained for each centre from all participating countries and are listed in online supplementary file 1. Primary results will be published in a peer-reviewed journal. Trial registration details ClinicalTrials.gov identifier: NCT03782792 ; Pre-results.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Psoriasis (Auckland, N.Z.) · 2026 · Journal Article
Liang Y, Deng B, Ntawuyamara E, Bachelez H, et al.
The Journal of investigative dermatology · 2025 · Clinical Trial, Phase II
Farag A, Visvanathan S, Bachelez H, Morita A, et al.
Clinical and experimental dermatology · 2023 · Journal Article
Salle R, Tubach F, Arlegui H, Curmin R, et al.
Experimental dermatology · 2023 · Editorial
Choon SE, Barker J, Bachelez H
The British journal of dermatology · 2023 · Journal Article
Burden AD, Bachelez H, Choon SE, Marrakchi S, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2022 · Journal Article
Assan F, Husson B, Hegazy S, Seneschal J, et al.
The British journal of dermatology · 2022 · Journal Article
Bachelez H
Acta dermato-venereologica · 2022 · Journal Article
Bettuzzi T, Bachelez H, Beylot-Barry M, Arlégui H, et al.
The New England journal of medicine · 2021 · Clinical Trial, Phase II
Bachelez H, Choon SE, Marrakchi S, Burden AD, et al.
JAAD case reports · 2021 · Journal Article
Assan F, Sbidian E, Bachelez H
Journal of the American Academy of Dermatology · 2023 · Randomized Controlled Trial
Elewski BE, Lebwohl MG, Anadkat MJ, Barker J, et al.
Dermatology and therapy · 2023 · Journal Article
Morita A, Choon SE, Bachelez H, Anadkat MJ, et al.
Dermatology and therapy · 2024 · Journal Article
Gordon KB, Blauvelt A, Bachelez H, Coates LC, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2024 · Journal Article
Strober B, Bachelez H, Crowley J, Elewski BE, et al.
The Journal of investigative dermatology · 2026 · Journal Article
Wei J, Wang Y, Chen Y, Wang Z, et al.
The British journal of dermatology · 2022 · Journal Article
Choon SE, Bachelez H
The British journal of dermatology · 2022 · Letter
Bechman K, Cook ES, Dand N, Yiu ZZN, et al.
Dermatology (Basel, Switzerland) · 2022 · Journal Article
Jendoubi F, Balica S, Richard MA, Chiaverini C, et al.
JAMA dermatology · 2025 · Journal Article
Choon SE, van de Kerkhof P, Bachelez H
JAMA dermatology · 2024 · Journal Article
Choon SE, van de Kerkhof P, Gudjonsson JE, de la Cruz C, et al.
JAAD international · 2026 · Journal Article
Zhou Z, Yao X, Su J, Shen M, et al.
Expert review of clinical immunology · 2022 · Journal Article
Bachelez H, Barker J, Burden AD, Navarini AA, et al.
Journal of the American Academy of Dermatology · 2026 · Journal Article
Reguiai Z, Fougerousse AC, Bachelez H, Fredeau L, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · Journal Article
Paris C, Curmin R, Gouillon L, Giboin C, et al.
The British journal of dermatology · 2023 · Journal Article
Aubert H, Arlegui H, De Rycke Y, Bachelez H, et al.
The Journal of experimental medicine · 2026 · Journal Article
Bronnec P, Dalmon S, Briand C, Allatif O, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2024 · Letter
Bachelez H, Griffiths CEM, Papp KA, Hall S, et al.
The Journal of investigative dermatology · 2024 · Comparative Study
Aevermann BD, Di Domizio J, Olah P, Saidoune F, et al.
NEJM evidence · 2026 · Journal Article
Smieszek S, Przychodzen B, Tyner C, Johnson C, et al.
JAAD international · 2026 · Journal Article
Zhou Z, Yao X, Su J, Shen M, et al.
Infection and Risk of Psoriasis and Atopic Dermatitis: A Systematic Review and Meta-Analysis
Supplementary tables and figures for the paper titled "Infection and Risk of Psoriasis and Atopic Dermatitis: A Systematic Review and Meta-Analysis".
Infection and Risk of Psoriasis and Atopic Dermatitis: A Systematic Review and Meta-Analysis
Supplementary tables and figures for the paper titled "Infection and Risk of Psoriasis and Atopic Dermatitis: A Systematic Review and Meta-Analysis".
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Dermatology (Basel, Switzerland) · 2022 · Journal Article
Jendoubi F, Balica S, Richard MA, Chiaverini C, et al.
BMJ open · 2021 · Clinical Trial Protocol
Choon SE, Lebwohl MG, Marrakchi S, Burden AD, et al.